Market Outlook:

Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease. Increasingly, drug developers are focusing on subsets of first-line CLL patients, such as elderly patients or those who harbor chromosome 17p deletions. The high unmet need for novel therapies with better efficacy and improved safety and tolerability profiles for the therapeutic management of first-line CLL presents notable commercial opportunity for drug developers.

Questions Answered:

  • What are the treatment drivers and goals for first-line CLL? How do current therapies, such as Johnson & Johnson/Janssen/AbbVie’s Imbruvica, perform on these metrics?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the prevailing areas of unmet need and opportunity in first-line CLL? Are late-phase emerging therapies targeting these areas?
  • What trade-offs are surveyed hematological oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in first-line CLL?

Production Description: Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Table of contents

  • Detailed, Expanded Analysis (First-Line Chronic Lymphocytic Leukemia)
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Nonclinical Attributes
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Physician Rating of Treatment Drivers and Goals in First-Line Chronic Lymphocytic Leukemia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Stated vs. Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Chronic Lymphocytic Leukemia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in First-Line Chronic Lymphocytic Leukemia and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the First-Line Chronic Lymphocytic Leukemia Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy with Improved Overall Survival
        • Opportunity: A Novel Therapy That Improves Progression-Free Survival
        • Opportunity: A New Therapy That Offers Substantial Improvement in Complete Response
        • Opportunity: A Novel Therapy with a More-Favorable Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • First-Line Chronic Lymphocytic Leukemia Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Bibliography

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, , is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at University of Science & Technology, Hisar, India.


Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details